RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of “Hold” by Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has received a consensus rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $9.50.

A number of research analysts have weighed in on RAPT shares. Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a report on Wednesday. HC Wainwright reaffirmed a “neutral” rating on shares of RAPT Therapeutics in a report on Tuesday. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday. Wells Fargo & Company cut their price objective on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, UBS Group cut their price objective on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a report on Monday, September 9th.

RAPT Therapeutics Price Performance

Shares of RAPT Therapeutics stock opened at $1.28 on Friday. RAPT Therapeutics has a 1 year low of $1.25 and a 1 year high of $27.35. The firm has a fifty day moving average price of $1.96 and a 200 day moving average price of $3.05. The stock has a market cap of $44.68 million, a PE ratio of -0.46 and a beta of 0.33.

Hedge Funds Weigh In On RAPT Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of RAPT. Point72 Asset Management L.P. boosted its position in RAPT Therapeutics by 176,725.0% during the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock worth $2,157,000 after acquiring an additional 706,900 shares during the last quarter. Kingdon Capital Management L.L.C. boosted its position in RAPT Therapeutics by 55.3% during the first quarter. Kingdon Capital Management L.L.C. now owns 1,500,000 shares of the company’s stock worth $13,470,000 after acquiring an additional 534,172 shares during the last quarter. Federated Hermes Inc. boosted its position in RAPT Therapeutics by 188.7% during the second quarter. Federated Hermes Inc. now owns 796,080 shares of the company’s stock worth $2,428,000 after acquiring an additional 520,368 shares during the last quarter. Acadian Asset Management LLC boosted its position in RAPT Therapeutics by 4,183.3% during the second quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock worth $1,424,000 after acquiring an additional 456,275 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in RAPT Therapeutics by 21.2% during the first quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock worth $22,386,000 after acquiring an additional 436,629 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors and hedge funds.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.